Comparing Hydroxyurea and Pegylated Interferon-Alpha-2a in PV and ET

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen Oh, MD, discussed treatment options for steroid-refractory high-risk primary myelofibrosis based on the patient's platelet count.

In an interview with Targeted Oncology, Christopher Chambers, MD, discussed how primary care physicians are involved with the diagnosis of cancer and the challenges faced with early detection.

In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.

Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.

In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.